First Motorized Retrievable Transcatheter Aortic Valve (TAVI) System - VitaFlow Liberty™ received approval for marketing in China

Shanghai, China, 1 September 2021 — On 31st August 2021, MicroPort CardioFlow Medtech Corporation (CardioFlow Medtech), a subsidiary of MicroPort Scientific Corporation, announced that its transcatheter aortic valve system – the VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) – has received approval for marketing by China’s National Medical Products Administration (NMPA). As the first motorized retrievable transcatheter aortic valve system approved for marketing, VitaFlow Liberty™ leads as the first motorized retrievable system in the Transcatheter Aortic Valve Implantation (TAVI) market.

The VitaFlow Liberty™ is the next-generation product of the VitaFlow® Transcatheter Aortic Valve and Delivery System (“VitaFlow®”), approved for marketing in 2019. Inheriting the unique design from VitaFlow®, VitaFlow Liberty™ features a hybrid density stent with double-layer skirts and a bovine pericardial leaflet. The retrievable delivery system of VitaFlow Liberty™ comes with an innovative motorized handle, allowing for fast, stable and accurate release and retrieval. In addition, VitaFlow Liberty™ is currently the only delivery system in the Chinese market whose distal end can be bent 360 degrees, providing superior flexibility to help minimize blood vessel damage and reduce the risk of complications. The motorized handle also provides surgeons with better control over the retrieval and repositioning of the valve.

Guoming Chen, Executive Director and President of CardioFlow Medtech, said, “CardioFlow Medtech has an extensive product portfolio in the field of transcatheter aortic therapy, providing clinicians with comprehensive transcatheter aortic therapy solutions. The upgrade of VitaFlow Liberty™ lies in the unique features provided by the innovative delivery system, which further improve the surgical experience. We believe that our ability to continuously innovate will ensure the core competitiveness of our future products for the benefit of more patients.”

In addition to VitaFlow Liberty™, CardioFlow Medtech's first-generation Angelguide® preshaped super stiff guidewire (Angelguide®) was also approved for marketing. The guidewire features high support and smooth transition for guidewire and guide trail, thus reducing blood vessel damage and improving release precision.

Dr. Qiyi Luo, Chief Technology Officer of MicroPort® and Chairman of the Board of Directors of CardioFlow Medtech, commentged, “Within years of the launch of VitaFlow®, the product is already used in more than 220 heart centers across China, allowing MicroPort® to become a key player in the Chinese heart valve market. We are now more confident and motivated to accelerate our development of medical devices for valvular heart disease. With the market launch of the VitaFlow Liberty™ System, CardioFlow Medtech will be able to better meet clinical needs, and provide better clinical outcomes.”

About CardioFlow Medtech

Founded in 2015, Cardioflow Medtech (stock code: 02160), a subsidiary of MicroPort Scientific Corporation (stock code: 00853), focuses on the research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases. In light of today’s rapidly growing yet severely under-penetrated heart valve medical device market, Cardioflow Medtech has seized this opportunity to strategically focus its product portfolio on the treatment of the most common aortic and mitral valve diseases. In the future, Cardioflow Medtech will strive to provide more innovative products and services to more doctors and patients across the globe.